Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00976599 · ClinicalTrials.gov registry record · Phase 2

A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis

A Phase 2 study of Rheumatoid Arthritis, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
29
Enrollment target
15
Study locations

NCT00976599 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by Pfizer. The registered enrollment target is 29 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 15 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00976599, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
29 participants
Enrollment target
15
Study locations

Study Summary

To explore the effect of CP-690,550 on blood and synovial markers in subjects with rheumatoid arthritis. To evaluate the safety, tolerability and efficacy of CP-690,550.

Conditions Studied

Rheumatoid Arthritis

Interventions

  • DRUG CP-690,550 + methotrexate
  • DRUG Placebo + Methotrexate

Study Locations (15)

Texas

  • Pfizer Investigational Site - Dallas
  • Pfizer Investigational Site - Dallas
  • Pfizer Investigational Site - Mesquite
  • Pfizer Investigational Site - Sunnyvale

Alabama

  • Pfizer Investigational Site - Birmingham
  • Pfizer Investigational Site - Birmingham
  • Pfizer Investigational Site - Birmingham

Ohio

  • Pfizer Investigational Site - Mayfield Village
  • Pfizer Investigational Site - Mentor
  • Pfizer Investigational Site - Willoughby

Washington

  • Pfizer Investigational Site - Seattle
  • Pfizer Investigational Site - Seattle

California

  • Pfizer Investigational Site - La Jolla

Maryland

  • Pfizer Investigational Site - Frederick

Michigan

  • Pfizer Investigational Site - Battle Creek

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2009-11
Est. Completion 2011-07
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00976599

The ClinicalTrials.gov registry entry for NCT00976599 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which CP-690,550 + methotrexate is the first listed.

NCT00976599 reports 15 study locations spanning 7 distinct geographic areas - top geographies include Texas, Alabama, Ohio.

Frequently Asked Questions

What is clinical trial NCT00976599 about?

NCT00976599 is a clinical study titled "A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis". To explore the effect of CP-690,550 on blood and synovial markers in subjects with rheumatoid arthritis. To evaluate the safety, tolerability and efficacy of CP-690,550.

What is the current status of trial NCT00976599?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2009-11. Estimated completion is 2011-07.

What conditions does trial NCT00976599 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT00976599?

The interventions under investigation include: CP-690,550 + methotrexate (DRUG), Placebo + Methotrexate (DRUG).

Who is sponsoring clinical trial NCT00976599?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00976599 being conducted?

This trial has 15 study locations across Alabama, California, Maryland, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.